A Food and Drug Administration committee is deciding whether to recommend approval for GlaxoSmithKline's Ariflo, a new type of drug developed to treat a serious lung conditin: chronic obstructive pulmonary disease. There is concern Ariflo may cause blood vessel inflammation, and the panel is deciding if the drug's benefits outweigh its risks.

Related Summaries